Chargement en cours...
MiR-122 Targets SerpinB3 and Is Involved in Sorafenib Resistance in Hepatocellular Carcinoma
The only first-line treatment approved for advanced hepatocellular carcinoma (HCC) is sorafenib. Since many patients experience drug resistance, the discovery of more effective therapeutic strategies represents an unmet clinical need. MicroRNA (MiR)-122 is downregulated in most HCCs, while oncogenic...
Enregistré dans:
| Publié dans: | J Clin Med |
|---|---|
| Auteurs principaux: | , , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
MDPI
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6406326/ https://ncbi.nlm.nih.gov/pubmed/30717317 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm8020171 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|